Clinical trials: Axillary Lymph Node Metastasis
Breast Cancer
Feasibility of Carbon-Dye Marking of Axillary Lymph Nodes Before Neoadjuvant Chemotherapy in Patients With Breast Cancer
Although treatment is started with surgery in early stage tumors depending on the molecular subtype, neoadjuvant chemotherapy is the initial treatment in locally advanced tumors or if axillary lymph node involvement is present.
- Trial name
- NCT05735795
- Testing
- Carbon Black Tattoo
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Gaziosmanpasa Research and Education Hospital
Invasive Breast Cancer, Axillary Metastases
Sentinel Lymph Node After Neoadjuvant Chemotherapy in Breast Carcinoma
Sentinel lymph node dissection (SLND) after NAC, aimed to reduce the rate of unnecessary axillary lymphadenectomy, is not a standard of care in case of patient with previously involved node before NAC because of a too high false…
- Trial name
- GANEA3 (NCT03630913)
- Testing
- Tagged axillary metastatic node
- Where
- 18 sites in France
- Volunteers
- 385 people
- Sponsor
- Institut Cancerologie de l'Ouest
Carcinoma, Lobular
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma
This study aims to explore the diagnostic validity of [18F]FES PET/CT for the evaluation of axillary lymph node metastasis in patients with invasive lobular breast cancer having clinically suspected or confirmed axillary lymph…
- Trial name
- NCT05960201
- Testing
- [18F]fluoroestradiol (FES)
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Asan Medical Center
Breast Cancer
Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.
Since the introduction of sentinel node biopsy in breast cancer, it has become clear that its use is reliable and reproducible. Today, it is clinical routine to not remove further lymph nodes from the axilla (arm pit) in case the…
- Trial name
- NCT02240472
- Testing
- Omission of axillary clearance
- Where
- 33 sites in Denmark, Greece and 1 more
- Volunteers
- 2,766 people
- Sponsor
- Karolinska Institutet
Breast Cancer
Characterizing Breast Cancer With 68Ga-FAPI PET/CT (PFB-01)
Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts (CAFs), which constitute a major proportion of cells within the tumor microenvironment, especially in breast cancer.
- Trial name
- NCT05574907
- Testing
- 68Ga-FAPI PET/CT scan
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Peking Union Medical College Hospital
Micrometastases, Neoadjuvant Chemotherapy
Micrometastases in Axillary Lymph Nodes in Breast Cancer, Post-neoadjuvant Chemotherapy
This study aims to investigate the significance of minimal residual axillary disease following NAC, with a particular focus on micrometastases (ypNmi), in comparison to pathologic lymph node-negative (ypN0) or macrometastases…
- Trial name
- NCT06149884
- Testing
- Sentinel lymph node biopsy, axillary lymph node dissection
- Volunteers
- 978 people
- Sponsor
- Gangnam Severance Hospital
Breast Cancer, Female
99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes
An open-label, single center study with 99mTc-ADAPT6 SPECT and biopsies of primary tumour and metastatic lymph nodes in breast cancer patients, where the primary endpoint of the study is to find out the correlation between the…
- Trial name
- 99mTc-ADAPT6 (NCT05412446)
- Testing
- ADAPT6-SPECT
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Breast Cancer Lymphedema
Axillary Reverse Mapping (ARM) in Breast Cancer Surgery to Prevent Lymphedema. (ARMtrial)
Breast cancer related lymphedema (BCRL) is a debilitating and distressing condition affecting approximately one out of five breast cancer survivors.
- Trial name
- NCT03333226
- Testing
- Axillary Reverse Mapping (ARM)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University Hospital of Ferrara